Investigating the effect of frankincense capsules on premenstrual syndrome and menstrual pai

Phase 2

Recruiting

Conditions: Condition 1: Dysmenorrhea. Condition 2: Premenstrual Syndrome.
Primary dysmenorrhea
Premenstrual tension syndrome
N94.4
N94.3

Registration Number: IRCT20230702058648N1

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Female

Target Recruitment: 62

Inclusion Criteria

1. Age 18 to 35 years. 2. Regular menstrual cycles. 3. Suffering from premenstrual syndrome and primary moderate to severe dysmenorrhea at the same time. 4. Being single. 5. Resident in the dormitory of Mashhad University of Medical Sciences. 6. Not taking certain drugs. 7. Not using alcohol or drugs and tobacco. 8. Not having depression, anxiety and extreme stress. 9. Lack of diet. 10. Not using medicinal and traditional treatments to reduce the symptoms of premenstrual syndrome and dysmenorrhea. 11. BMI less than 30. 12. Absence of specific medical disease. 13. Absence of known gynecological issues such as fibroids and endometriosis. 14. The absence of stressful events in the past 6 months. 15. Not engaging in sports professionally.

Exclusion Criteria

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Average total score of premenstrual syndrome symptoms. Timepoint: Calculation of the average score of premenstrual syndrome symptoms at the beginning of the study (before the start of the intervention) and 1 and 2 months after the start of the intervention. Method of measurement: The mean total score of premenstrual syndrome symptoms will be evaluated by the Calendar of Premenstrual Events (COPE) form, as self-reported by the patients.;Average total score of severity and duration of primary dysmenorrhea. Timepoint: Calculation of the average score of severity and duration of dysmenorrhea at the beginning of the study (before the start of the intervention) and 1 and 2 months after the start of the intervention. Method of measurement: The mean total score of dysmenorrhea intensity by the visual pain scale (VAS) and the mean total score of pain duration by the scale COX menstrual scale will be investigated in the form of self-reporting by patients.

Secondary Outcome Measures